跳至主要内容
临床试验/CTRI/2020/09/027547
CTRI/2020/09/027547尚未招募2 期

Efficacy of Pomalidomide-Bortezomib-Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma: A Phase II Study

JIPMER0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
JIPMER

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Eligible patients are those with
  • 1.Newly diagnosed, treatment-naive multiple myeloma (as defined by the IMWG Criteria), who are of age >= 18years and <75years, belonging to both sexes
  • 2.ECOG performance status 0-2
  • 3.Patients must meet the following laboratory criteria within 14days of treatment
  • a.Absolute neutrophil count >=1000/L
  • b.Platelet count >= 50,000/L
  • c.Adequate hepatic function defined as TB, AST/ALT <3 x ULN
  • d.Creatinine clearance >=15ml/min

排除标准

  • 1.Past history of plasmacytomas
  • 2.Clinically relevant active infection or serious co-morbid medical or psychiatric illness
  • 3.Pregnancy or lactation
  • 4.Known hypersensitivity/contraindications to any of the drugs in the regimen
  • 5.Known HIV infection, active hepatitis B or C viral infection

研究者

发起方
JIPMER

相似试验